Erbb2 Mutation Profiling With Next-Generation Sequencing (Ngs) In Solid Tumors.

e24264Background: ERBB2 (HER2) is a member of the human epidermal growth factor receptor family. HER2 amplification or over-expression has been shown to play an important role in the development and treatment of breast cancer and gastric cancer. Recently HER2 mutations have been found in non-small-cell lung cancer (NSCLC). However, mutation profiling of HER2 and its therapeutic potential in other solid tumors have not been clearly demonstrated. Methods: We retrospectively reviewed gene test results of 6000 solid tumor samples in our institute. Tumor biopsy, ctDNA or pleural effusion samples were analyzed using hybridization capture-based NGS ER-seq method, which enables simultaneously assess single-nucleotide variants(SNV), insertions/deletions (indel), rearrangements and somatic copy-number(CNV) viriation at least 59 genes (range 59-1021 genes). Results: One hundred and forty seven cases with HER2 alterations were identified, including 53 breast cancer (BC), 62 lung cancer (LC), 10 colorectal cancer (CRC...